Colorectal Surgery in Cirrhosis study (CSi Cirrhosis)

  • Research type

    Research Study

  • Full title

    Colorectal Surgery in Cirrhosis study (CSi Cirrhosis)

  • IRAS ID

    296478

  • Contact name

    John Hammond

  • Contact email

    john.hammond8@nhs.net

  • Sponsor organisation

    Newcastle Upon Tyne Hospitals NHS Foundation Trust

  • Clinicaltrials.gov Identifier

    NCT00000000

  • Duration of Study in the UK

    2 years, 8 months, 31 days

  • Research summary

    The overall incidence of chronic liver disease (CLD) is rising across the UK. CLD significantly increases the risk of complications and at least doubles the risk of dying after bowel surgery. In patients with CLD who require bowel surgery for cancer this increased risk can mean that some patients do not access potentially curative treatment for bowel cancer and that some patients develop complications because adequate risk assessment was not undertaken before surgery.

    Currently we lack a reliable method of identifying which patients with CLD are more at risk of having complications or dying after bowel surgery. An important complication of CLD is the development of high pressure in the liver blood vessels. This high pressure is called portal hypertension. Measuring this pressure can predict the risk of complications in other types of abdominal surgery. In Newcastle we regularly assess patients with CLD where there is concern about the risk of undertaking bowel surgery for cancer. We routinely use liver pressure measurements with an invasive test as part of our assessment process to determine the severity of liver disease. This information helps patients and their bowel surgeons make decision about the approach to bowel surgery and its risks.

    The aim of this study is to determine the feasibility of delivering this assessment process using both invasive (HVPG) and non-invasive (transient elastography + MRI) tests to measure liver blood pressure and use the data from this feasibility study to help design a larger national multicentre trial.

  • REC name

    East of Scotland Research Ethics Service REC 2

  • REC reference

    22/ES/0016

  • Date of REC Opinion

    21 Jun 2022

  • REC opinion

    Further Information Favourable Opinion